Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 1;28(5):485-491.
doi: 10.1097/MCP.0000000000000892. Epub 2022 Jul 16.

The role of PET in the management of sarcoidosis

Robert J Vender  1 , Hamad Aldahham  2 , Rohit Gupta  3
Affiliations
Review

The role of PET in the management of sarcoidosis

Robert J Vender et al. Curr Opin Pulm Med. .

Abstract

Purpose of review: PET has emerged as method to determine the location and extent of disease activity in sarcoidosis. As most clinicians do not routinely utilize PET in the management of sarcoidosis, an understanding of the imaging technique is needed to comprehend the impact that PET abnormalities have on diagnosis, prognosis, and treatment.

Recent findings: Although PET can detect inflammation because of sarcoidosis throughout the body, it is most often utilized for the diagnosis of cardiac sarcoidosis for which it may provide information about prognosis and adverse events. Whenever PET is combined with cardiac magnetic resonance (CMR), clinicians may be able to increase the diagnostic yield of imaging. Furthermore, PET abnormalities have the potential to be utilized in the reduction or augmentation of therapy based on an individual's response to treatment. Although various biomarkers are used to monitor disease activity in sarcoidosis, an established and reproducible relationship between PET and biomarkers does not exist.

Summary: PET has the potential to improve the diagnosis of sarcoidosis and alter treatment decisions but prospective trials are needed to define the role of PET while also standardizing the performance and interpretation of the imaging modality.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Box 1
Box 1
no caption available
FIGURE 1
FIGURE 1
Axial and coronal views of PET scan in patient with cardiac sarcoidosis. Methods: this is an original PET image from the authors’. Results: panel a shows disease activity in the left apical (SUV of 22.6) and septum (SUV of 21.6). Panel b shows a reduction in SUV after treatment (SUV 4.2 and 5.7 respectively). Panel c shows apical and septal disease in the coronal view.
FIGURE 2
FIGURE 2
Pulmonary parenchymal changes because of sarcoidosis on computed tomography and corresponding PET findings. Methods: this is an original PET image from the authors. Results: the top image was obtained from computed tomography and shows parenchymal architectural changes while the bottom image shows increase FDG uptake by PET in the corresponding location.
FIGURE 3
FIGURE 3
FDG-PET findings in multisystem sarcoidosis. Methods: this is an original PET image from the authors. Results: the image on the left demonstrated FDG uptake in the heart while the image on the right reveals multisystem disease involving the liver, spleen, right acetabular bone, and lymph nodes in the low cervical, supraclavicular, mediastinal, and hilar regions. Both images are from the same individual at different rime intervals of the disease course.
FIGURE 4
FIGURE 4
Consecutive FDG-PET scans in patient with multisystem sarcoidosis. Methods: this is an original PET image from the authors’. Results: this figure shows three consecutive FDG-PET performed in a patient with progressively more aggressive therapy for sarcoidosis.
See this image and copyright information in PMC

References

    1. Lee S, Birnie D, Dwivedi G. Current perspectives on the immunopathogenesis of sarcoidosis. Respir Med 2020; 173:106161. - PubMed

    2. This review discussed the role of the innate and adaptive immune system in generating the inflammation from sarcoidosis. It also discussed the current literature in regards to possible causes including auto-immunity.

    1. Hunninghake GW, Costabel U, Ando M, et al. . Statement on sarcoidosis. An J Respir Crit Care Med 2012; 160:736–755. - PubMed
    1. Crouser ED, Maier LA, Baughman RP, et al. . Diagnosis and detection of sarcoidosis. An official American Thoracic Society Clinical Practice guideline 2020; 201:E26–E51. - PMC - PubMed
    1. Adams H, Keijsers RG, Korenromp IHE, Grutters JC. FDG PET for gauging of sarcoid disease activity. Semin Respir Crit Care Med 2014; 35:352–361. - PubMed
    1. Fu Y, Maianu L, Melbert BR, Garvey WT. Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol Dis 2004; 32:182–190. - PubMed

MeSH terms

Substances